ImmunityBio, Inc. (NASDAQ:IBRX) Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC raised its position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 20.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 549,905 shares of the company's stock after acquiring an additional 94,200 shares during the period. Rafferty Asset Management LLC owned approximately 0.08% of ImmunityBio worth $1,408,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Mutual Advisors LLC purchased a new position in shares of ImmunityBio in the fourth quarter worth $41,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of ImmunityBio by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 147,754 shares of the company's stock worth $378,000 after buying an additional 13,788 shares during the last quarter. Stephens Inc. AR purchased a new position in shares of ImmunityBio in the fourth quarter worth $26,000. New York State Common Retirement Fund raised its holdings in shares of ImmunityBio by 62.8% in the fourth quarter. New York State Common Retirement Fund now owns 32,418 shares of the company's stock worth $83,000 after buying an additional 12,500 shares during the last quarter. Finally, Handelsbanken Fonder AB raised its holdings in shares of ImmunityBio by 71.2% in the fourth quarter. Handelsbanken Fonder AB now owns 92,300 shares of the company's stock worth $236,000 after buying an additional 38,400 shares during the last quarter. 8.58% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio Price Performance

Shares of ImmunityBio stock opened at $2.90 on Wednesday. The firm has a fifty day moving average price of $2.64 and a 200 day moving average price of $3.25. ImmunityBio, Inc. has a 1 year low of $1.83 and a 1 year high of $7.63. The stock has a market cap of $2.56 billion, a PE ratio of -3.15 and a beta of 0.33.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The company had revenue of $16.52 million for the quarter, compared to analysts' expectations of $17.50 million. As a group, equities analysts expect that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on IBRX. Piper Sandler raised shares of ImmunityBio from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $4.25 to $5.00 in a report on Tuesday. D. Boral Capital reaffirmed a "buy" rating and issued a $30.00 price target on shares of ImmunityBio in a report on Monday, May 12th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price target on shares of ImmunityBio in a report on Monday, May 12th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $12.25.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.

Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. (NASDAQ:IBRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.